Monoclonal antibody against H1N1 influenza virus hemagglutinin cross reacts with hnRNPA1 and hnRNPA2/B1.

Following influenza A vaccination, certain individuals exhibit adverse reactions in the nervous system, which causes a problem with the safety of the influenza A vaccine. However, to the best of our knowledge, the underlying mechanism of this is unknown. The present study revealed that a monoclonal antibody (H1-84mAb) against the H1N1 influenza virus hemagglutinin (HA) protein cross-reacted with an antigen from brain tissue. Total brain tissue protein was immunoprecipitated with this cross-reactive antibody, and mass spectrometry revealed that the bound antigens were heterogeneous nuclear ribonucleoprotein (hnRNP) A1 and hnRNPA2/B1. Subsequently, the two proteins were expressed in bacteria and it was demonstrated that H1-84mAb bound to hnRNPA1 and hnRNPA2/B1. These two proteins were expressed in three segments and the cross-reactivity of H1-84mAb with the glycine (Gly)-rich domains of hnRNPA1 (195aa-320aa) and hnRNPA2/B1 (202aa-349aa) was determined using ELISA blocking experiments. It was concluded that the Gly-rich domains of these two proteins are heterophilic antigens that cross-react with influenza virus HA. The association between the heterophilic antigen Gly-rich domains and the safety of influenza A vaccines remains to be investigated.